POLYMEDNSEPoly Medicure Limited· PharmaceuticalsMediumPositive
Announced Thu, 30 Apr · 20:08 IST

Poly Medicure Limited has informed the Exchange about Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Acquisition of Subsidiary

Listed Co AcquisitionStrategic Transactions View source PDF

POLYMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+6.4%1-day move
₹1519.00
prior close
₹1520.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.5+1.1+1.9+1.4+6.4+9.5+10.4+8.6+8.8+4.9+0.1-6.8+10.9
Up moveDown movePending
AI summary

Poly Medicure's wholly owned subsidiary, Polymed Brazil LTDA, has acquired 100% equity in MEDYNEO COMERCIO DE PRODUTOS PARA SAUDE LTDA, making it a step-down subsidiary effective April 29, 2026. The total cash consideration is Brazilian Reais (R$) 180,000 (roughly ₹27-28 lakhs). MEDYNEO is a newly registered entity (July 2025) with no past operations, employees, or turnover, but holds all the necessary licenses, permits, and registrations for importing and commercializing medical devices in Brazil. The deal is not a related party transaction. In essence, this is a strategic, low-cost acquisition aimed at giving Poly Medicure ready access to Brazil's medical device market through an existing licensed entity.

Likely market impact

Minimal immediate financial impact given the small deal size, but strategically important as it gives Poly Medicure a quick entry into the Brazilian medical devices market with all regulatory licenses already in place, potentially enabling future revenue growth from that geography.